JNCCN 360

Advertisement

Advertisement

Mansoor Raza Mirza, MD, on the Potential Role of PARP Inhibition Plus Immunotherapy in Ovarian Cancer

Alexander N. Shoushtari, MD, on Toxicities of Nivolumab

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone Disease: Denosumab and Zoledronic Acid

Recent

FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Merkel Cell Carcinoma

FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Melanoma

Cemiplimab-rwlc Approved for Advanced Cutaneous Squamous Cell Carcinoma in European Union

Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?

Published

Medical Literature

Use of Avelumab in Merkel Cell Carcinoma: Linking Early Response With Overall Survival

Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer

Meta-analysis of Treatment of Skin Cancers With PD-1/PD-L1 Inhibitors

Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial

Ongoing

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Immunotherapy for cSCC: How, Why, and When (login required)

Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers

The Emerging Role of Immunotherapy in Head and Neck Cancers: An Integrated Approach (login required)

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

Center for Immunotherapy Clinical Research Trials

ClinicalTrials.gov Immunotherapy

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.